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relapse is excluded, therapeutic lumbar punctures and in severe
cases corticosteroids.
A priority in IRIS research is identifying key inﬂammatory path-
ways that trigger the condition that could be targeted with more
speciﬁc immunotherapy to prevent and/or treat the condition.
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Abstract: With the advent of antiretroviral therapy (ART), HIV
has shifted to a chronic manageable condition, even in resource-
limited settings. Now, the long-term effects of being on ART and
living with HIV are emerging. These include the adverse effects of
long-term ART and morbidity due to non AIDS complications such
as cardiovascular, hepatic, renal,metabolic and neurocognitive dis-
ease, cancers and ageing as well as complications due to hepatitis
B and C co-infection. Although ﬁrst and second-line antiretrovirals
are available in resource-limited settings, new antiretrovirals are
urgently needed in order to sustain HIV as a chronic manageable
condition. Several clinical trials are underway to eradicateHIV from
reservoirs among patients who are on long-term ART and virologi-
cally suppressed, leading to the hope of eventual eradication of this
virus.
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Abstract: Visceral leishmaniasis is the most severe form of
leishmaniasis, and if untreated, it is fatal. Although pentavalent
antimony (Sbv) ismostwidelyuseddrug for its treatment, but in the
state of Bihar in India and in Nepal moderate to severe resistance
to Sbv led to it being abandoned in the Indian subcontinent. Gov-
ernments of India Nepal and Bangladesh lauched an elimination
initiative for visceral leishmaniasis (VL) in 2005 and oral miltefo-
sine was selected for treatment. Prolonged regimen of almost one
month, frequent gastrointestinal adverse events and teratogenic
potential are major hurdles of the miltefosine treatment leading
to poor compliance. Further, long half life of miltefosine makes
it vulnerable for drug resistance. Recently two important break-
throughs in the treatment of VL provide new perspective in the
control of VL in Indian subcontinent. In a randomized controlled
study over 300 parasitologically conﬁrmed patients were treated
with single dose of 10 mg/kg of liposomal amphotericin B (AmBi-
some, L-AmB). The cure rate was 95.7% which was comparable to
the comparator conventional amphotericin B (96.3%) . In another
phase 3 study which closely followed the single dose study mul-
tiple combinations of the three available drug, L-AmB, miltefosine
and paromomycin were administered between 8-11 days. In this
open labelled, randomized, controlled, non-inferiority trial inBihar,
India, single injection of 5 mg/kg L-AmB and 7-day miltefosine;
L-AmB and 10-day paromomycin; miltefosine and paromomycin
for 10 days were compared with the conventional treatment. The
efﬁcacy rates for all patients enrolled (intent to treat, ITT) were:
amphotericin B 93.0%; L-AmB and miltefosine 97.5% ; L-AmB and
paromomycin 97.5%; miltefosine and paromomycin 98.7% (95.06-
99.78). Combination therapies were well tolerated and had fewer
adverse events than standard treatment. These studies provide
newer vistas in the treatment of VL. Their early implementation
will provide a tremendous boost to the Elimination programme.
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